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Diabetes mellitus, which is a metabolic disease resulting from insulin deficiency or diminished 
effectiveness of the action of insulin or their combination, is recognized as a major threat to 
human life. Using drugs on a long term to control glucose can increase the hazards of 
cardiovascular disease and some cancers. Therefore, there is an urgent need to discover new, 
safe, and effective antidiabetic drugs. Traditionally, there are several plants that are used to 
treat/control diabetes by South African traditional healers such as Brachylaena discolor. This 
study aimed to isolate and identify antidiabetic compounds from B. discolor.  
 
The plant materials of B. discolor was collected from University of KwaZulu-Natal botanical 
garden. Plant materials were dried under the fume hood for two weeks and ground to a fine 
powder. The powder was extracted with a mixture of dichloromethane and methanol (1:1). To 
investigate the antidiabetic activity, the prepared extract was tested in vitro for glucose 
utilization in a muscle cell line. The results revealed that blood glucose levels greater than 20 
mmol/L, which measured after 24 and 48 hours of the experimental period, three fractions had 
positive (*p<0.05) antidiabetic activity compared to the control. The DCM:MeOH (1:1) extract 
of  B. discolor leaves was subjected to column chromatography, yielding five fractions (A, B, 
C, D, and E). Fraction A yielded lupeol acetate and its Δ12-isomer as a mixture of compounds. 
Two compounds identified as β-sitosteryl linelonate, and α-tocopherol were obtained from 
fraction B. Fraction E resulted in the isolation of genkwanin 5-O-β-D-glucopyranoside and a 
mixture of the α- and β-isomers of glucose. 
 
The results of this study confirmed the antidiabetic properties of the leave extract B. discolor, 
which support the traditional use of the plants by healers. However, further research to 
investigate more compounds in this plant as well as testing the side effect of using these 
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CHAPTER 1: INTRODUCTION 
 
1.1 GENERAL INTRODUCTION 
 
The World Health Organization (WHO) defines diabetes mellitus (DM) as “a chronic 
disease that occurs, either because the pancreas does not produce sufficient amounts of 
insulin, or the body cannot efficiently use the produced insulin”.1 Diabetes is considered as 
a controllable but not treatable disease. The WHO has reported a worldwide increase of 
diabetes in 2014, with an estimated 422 million cases in comparison to 108 million cases 
in 1980.2 In addition, the prevalence of diabetes has almost doubled since 1980, increasing 
from 4.7% to 8.5% of the population with about 1.5 million deaths in 2012.2 This disease 
can be controlled by direct therapies including insulin and other antidiabetic agents. Lately, 
people also turn to the use of herbal medicine and natural products because of their 
availability, low cost, and less side effects.3 
The use of traditional medicine resulted from the combination of knowledge, skills, and 
practices which were established  based on the observations, beliefs, and experiences in 
different cultures.4 Major civilizations of the ancient world, e.g. Chinese, Indians, and 
Africans, provide strong evidence for the use of medicinal plants as therapy for a large 
diversity of illnesses.5 Recently, people turned back to the use of medicinal plants due to 
adverse effects and cost of chemically synthesized drugs. Also, a large part of the 
population of the world consider traditional medicine as an essential element of their health 
care.4 The basic components of herbal medicines are plants and plant products, minerals, 
and animals; generally, this medication is usually used on the body surface or inserted into 
the body.6 
In organic chemistry, the term ‘natural products’ is used to describe purified organic 
components isolated from natural sources that are produced by secondary metabolic 
pathways.7 Secondary metabolites often have the right chiral configuration to influence 
biological activity, without a “primary” function directly involved in the usual growth of 
an organism or its development.8 It usually has a molecular weight of less than 1500 amu.7 
Several studies (e.g., Doughari,9 Abo et al.,10 and Nweze et al.11) reported that the 
secondary metabolites are responsible for plant protection from microbial infections. In 
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this context, Duraipandiyan et al.12 evaluated 18 ethnomedicinal plant extracts for activity 
against nine bacterial and one fungal strain. They found that the plant extracts exhibited 
antimicrobial activity against the microorganisms at different concentrations. 
Some of the old successes in the isolation of active compounds from plants are the isolation 
of the antimalarial agent quinine (1.1), which was isolated from the bark of Cinchona 
species and the development of the anti-inflammatory drug acetylsalicylic acid (1.2) 
(aspirin) from the natural products salicylic acid and salicin (1.3) isolated from the bark of 
the willow tree Salix alba L.13 In addition, many alkaloid compounds such as morphine 
(1.4) isolated from Papaver somniferum L. (opium poppy) have been used as painkillers. 
Penicillin G (1.5), a well-known and one of the most famous natural products discovered 
in 1929, is derived from a fungus (microorganism) and have been used as an antibiotic.14 
 
Betulinic acid (1.6) is a natural product isolated from Betula pubescens Ehrh. bark and was 
recognized as an HIV inhibitor.15 Betulinic acid also has anticancer properties, because it 
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has been found to induce apoptotic cell death in cancer cells.16 Paclitaxel (Taxol®) (1.7), 
which was isolated from the bark of Taxus brevifolia Nutt. (Pacific yew), is the common 
drug for the treatment of breast cancer.17 In addition, there are other antitumour compounds 
such as ingenol 3-O-angelate (1.8), a derivative of the polyhydroxy diterpenoid ingenol, 
which was isolated from Euphorbia peplus L. sap and is currently under clinical trials for 
the treatment of skin cancer.18 
Digitalis purpurea L. (foxglove) contains four important glycosides and three of them are 
cardiac stimulants. The most powerful of the isolated compound is digitoxin (1.9), which 
has been used to treat heart cases through increasing the strength of the muscle tissue, 
especially heart and arterioles muscle.19 Digitoxin and its analogues are also used in 
congestive heart failure control. However, their possible long-term negative effects lead to 


























































PG490-88 (1.10), which is also known as 14-succinyl triptolide sodium salt, was isolated 
from the vines and roots of Tripterygium wilfordii Hook.f., and is conventionally used by 
the Chinese for the treatment of inflammatory diseases affecting the immune system.20 
Other compounds, such as triptolide (1.11) obtained from the Tripterygium vine, are 
recognized as effective immunosuppressive compounds.20 
 
 
4 | P a g e  
 
 
One of the most common drugs used to treat diabetes, metformin, was first isolated from a 
plant, Galega officinalis L.21 
1.2 AIMS AND OBJECTIVES OF THIS DISSERTATION  
 
The aim of this thesis was to investigate Brachylaena discolor DC, a plant used traditionally 
for the treatment of diabetes.  
 
The specific objectives were to: 
 
• Confirm the antidiabetic activity of an extract of the leaves of B. discolor. 
• Isolate the compounds in the extract. 
• Determine the structure of the isolated compounds. 
 
The rest of the thesis consists of three chapters as follows: 
 
Chapter 2 provides an intensive literature review on diabetes and the medications used for 
the treatment thereof. In addition, the medicinal plants used for the treatment of diabetes in 
South Africa are discussed. Chapter 3 provides information about the medicinal plant (B. 
discolor) used in this study, including its taxonomy, description, distribution (in South 
Africa), and the phytochemistry of the species and Brachylaena genus. The procedures of 
isolating the components from Brachylaena discolor in this investigation are described. 
The presentation of the results and the associated discussions are also covered in this 
chapter. Finally, Chapter 4 provides a general conclusion and the implications of the 
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CHAPTER 2: DIABETES AND MEDICINAL PLANTS: A 
LITERATURE REVIEW 
 
2.1 DEFINITION AND SYMPTOMS OF DIABETES  
 
Diabetes mellitus is a group of symptoms related to the metabolic process, characterized 
by high blood glucose (hyperglycaemia) following a combined defect in insulin secretion 
and action. Long-term hyperglycaemia can cause eye damage, heart, and nerve 
dysfunction, and kidney failure.22 The symptoms of diabetes mellitus can vary in 
individuals and sometimes there may be no signs. According to the International Diabetes 
Federation (IDF), the common symptoms of diabetes mellitus are a tendency to urinate 
more often, increased thirst, intense hunger, weight loss, tiredness, frequent infections, 
slow-healing wounds, and blurred vision.23 Some of the specific diabetes symptoms are 
related to a certain type of diabetes. 
 
2.2 CLASSIFICATION OF DIABETES 
 
There are several types of diabetes, with the most common three types as follows: 
 
• Type I: Insulin-dependent diabetes, which mostly results from the lack of insulin due 
to pancreatic beta cell destruction. This type of diabetes is usually diagnosed at a young 
age (children and young people) and can be treated using insulin injections. 
 
• Type II: Non-insulin-dependent diabetes is a combination of insulin resistance and an 
insufficient insulin secretion defect. This type of diabetes is more common than type I 
representing about 90% of the diabetes cases worldwide. It mainly results as a 
consequence of sedentary behaviour, bad dietary habits, and genetic factors.24 
 
• Gestational diabetes, commonly associated with pregnancy, is defined as a glucose 
intolerance that was not existing or known prior to pregnancy. In general, gestational 
diabetes mellitus affects about 2 to 5% of pregnant women and in most cases, may 
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increase the risk of developing type II (or, rarely, type 1) diabetes in the years following 
the delivery.25 
 
Other types of diabetes include a wide variety of relatively uncommon conditions such as 
diabetes associated with defects in specific genes, diseases of the pancreas, special drugs 
that affect or damage the pancreas, infections, and other conditions. 
 
When the blood glucose levels are higher than normal and at the same time not high enough 
to be diagnosed as diabetes, it is called prediabetes.26 Prediabetes usually increases the risk 
factors for developing type 2 diabetes. The Centers for Disease Control and Prevention 
reported that about 86 million adults in the USA had prediabetes in 2012.26 
 
Diabetes has become one of the greatest threats to human health in the 21st century and 
this is calling for increasing the efforts for its prevention and control.27 A recent estimation 
showed that diabetes affects about 70 million people in Asia, 64 million in America and 
the Caribbean, 55 million in Europe, and about 15 million in Africa.28 According to the 
most recent report of Stats South Africa, about 8% of the population in South Africa are 
affected by diabetes and it was recognized as the fifth most important disease that caused 
human death.29 
2.3 MEDICATIONS USED TO TREAT DIABETES  
 
Historically, symptoms of diabetic diseases were recorded 3,500 years ago, in Egypt, 
Arabia, and Asia. Diabetes has been diagnosed and medication for managing diabetes 
mellitus was discovered in the 20th century. The discovery of diabetic remedies such as 
insulin in 1922, significantly reduced death in the diabetic population.30 Since that time, 
the diabetic remedies and medications were greatly improved. Nowadays, the 
pharmacological controls of diabetes are more effective. The drugs used to manage 
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2.3.1 Insulin 
The discovery of insulin, a polypeptide, in 1922 was recognized as a major medicinal 
revolution in the treatment of diabetes.30 Insulin is a hormone that is vital for metabolic 
processes, and is released in the body by pancreatic cells. Insulin works by stimulating 
glycogen formation and this function helps to maintain lower glucose levels in the blood. 
The subsequent development of insulin analogs was geared to improve diabetes control 
and reduce or delayed complications.31 Although insulin is still considered as the basis for 
diabetes therapy, the discovery of new medications that can complement and enhance 
insulin action (e.g. sulfonylureas) were extremely important, because the pathophysiology 
of diabetes mellitus involves different mechanisms, which need to be considered.31 
2.3.2 Sulfonylureas 
Sulfonylureas are a class of oral antidiabetic compounds and are presently used as a second 
option to treat type 2 diabetes.32 Table 2.1 provides a summary of the available sulfonylurea 
drugs, their classification, dosage, and side effects. The sulfonylurea medications can be 
divided into two groups: group one includes chlorpropamide (2.1), tolazamide (2.2), and 
tolbutamide (2.3), which are representing the first-generation agents. This group has longer 
half-lives, increased occurrence of hypoglycaemia, and more drug interactions. On the 
other hand, glimepiride (2.4), glipizide (2.5), and glyburide (2.6) are considered as second-
generation agents (Fig. 2.1). The group of second-generation agents has a faster action, 
shorter half-lives, and a lower incidence of hypoglycaemia.33 
 
There are some agents offered in a combination with other antidiabetic treatments. For 
example, glipizide (2.5) and glyburide (2.6) are both available in combination with 
metformin (2.7), while glimepiride (2.4) is available in combination with each of the 
thiazolidinediones (pioglitazone (2.9) and rosiglitazone (2.10)).33 The sulfonylurea agents 
are not used in patients whose pancreas is not producing insulin (type 1 diabetes). Using 
sulfonylurea agents has many advantages (e.g. safe and cheap); however, the occurrence 
of hypoglycaemia is the major side effect.33 In Table 2.1, a summary of the available 
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Uses Side effect 
Chlorpropamide 
(2.1) 
100/200 Controlling blood sugar 
in type 2 DM. 
Mild nausea, 
vomiting, diarrhoea,  
hunger, skin rash, 
and redness, itching 
Tolazamide (2.2) 250/500 Control of mild to 
moderately severe, 
stable, type 2 DM 
Feeling of stomach 
fullness, nausea, and 
heartburn. 
Tolbutamide (2.3) 500 orally Helping the body use 
insulin efficiently with 
diet and exercise. 
Nausea, fullness, 
heartburn, headache, 
and changes in taste. 
Glimepiride (2.4) 1/2/4 orally Controlling of type 2 




Glipizide (2.5) 2.5/5/10 Reduce blood sugar 
levels which are caused 
by type 2 DM. 
Low blood sugar 
and stomach 
problems. 
Glyburide (2.6) 1.25/2.5/5 Adjunct to diet and 
exercise for the control 




and weight gain 





Adjunct to diet and 
exercise for improving 
glycaemic control 



























































































Figure 2.1.  Chemical structures of sulfonylurea agents used for diabetes. 
2.3.3 Metformin 
Metformin (glucophage) (2.7), a biguanide, is the major medicine used to treat type 2 
diabetes and is considered as significant for the control of the disease. Metformin was 
mainly developed and isolated from Galega officinalis L., (Fabaceae) a plant that was 
traditionally used in Europe as a diabetic drug.21 This drug decreases the amount of glucose 
released by the liver, which in turn lowers the sugar levels in the blood.34 It is used to treat 
insulin resistance associated with prediabetes, type 2 diabetes, and polycystic ovarian 
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syndrome. Metformin comes in tablet and in liquid form and the effective dose is 500 
mg/day, with an optimum dose of 2 000 mg/day. However, as with all medicines, there are 
common side effects such as upset stomach, bloating, gas, diarrhoea, decreased appetite, 
lower back or side pain and heartburn. 
 
 
2.3.4 Thiazolidinediones (TZDs) 
Thiazolidinediones (Fig. 2.2), also called glitazones, were first introduced in 1996 for the 
treatment of type 2 diabetes.35 The thiazolidinediones are a class of oral antidiabetic drugs 
that enhance metabolic processes in type 2 diabetes through the enhancement of insulin 
sensitivity.34 Although thiazolidinediones could be beneficial for the full insulin resistance 
syndrome, some of its members are known for their adverse side effects. For instance, 
troglitazone (2.8) was withdrawn from the market in 2000 due to idiosyncratic 
hepatoxicity, while pioglitazone (2.9) and rosiglitazone (2.10) continue to be widely used. 
These glitazones were found to be safe and is the most effective pharmacologic treatment 
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2.3.5 Meglitinides (glinides) 
There is a similarity between meglitinides (Fig. 2.3) and sulfonylureas in terms of action 
but with a few major differences. Meglitinides are relatively new drugs compared to 
sulfonylureas. Repaglinide (2.11) and nateglinide (2.12) were the first and second agents 
approved by the USFDA in 1997 and 2000, respectively. Meglitinide medication works by 
stimulating insulin release from the pancreas, which in turn lowers blood glucose levels.36 
There are two meglitinide drugs in the United States; repaglinide (Prandin)® and 
nateglinide (Starlix)® can be used alone or in a combination with other medications for type 
2 diabetes. The meglitinides can cause hypoglycaemia but at a rate lower than 
sulfonylureas.36 Other reported side effects of meglitinides agents are feeling shaky, 




Figure 2.3. Chemical structures of meglitinide agents used for type 2 diabetes. 
2.3.6 α-Glucosidase Inhibitors 
α-Glucosidase inhibitors (Fig. 2.4) are commonly used to treat patients with type 2 diabetes 
and have positive effects on glycaemic control but not on plasma lipids.37 α-Glucosidase 
inhibiting agents slow the absorption of particular carbohydrates from the small intestine 
which in turn lowers the effect on postprandial blood glucose and consequently the insulin 
levels. Acarbose (2.13), voglibose (2.14), and miglitol (2.15) are α-glucosidase drugs 
available for therapy. Acarbose and voglibose are effective and safe drugs to be used in 
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Figure 2.4. Chemical structures of α-glucosidase inhibitors used for type 2 diabetes. 
2.3.7 Glucagon-like Peptide (GLP)-1 and Dipeptidyl Peptidase 4 (DPP-4) 
Inhibitors 
Incretin mimetics are a relatively new class of pharmacological agents for treatment of type 
2 diabetes.39 These drugs work by increasing the incretin levels, which is a group of 
intestinal hormones that are excreted from enteroendocrine cells into the blood within 10-
15 minutes after eating.40 These hormones increase the insulin production required by the 
body and lessen released liver glucose when it is not necessary.41 In regards to incretin 
systems, two types of drugs have been modified: glucagon-like peptide (GLP)-1 receptor 
agonists (e.g. liraglutide (2.16) and exenatide (2.17)) and dipeptidyl peptidase 4 (DPP-4) 
inhibitors (e.g. sitagliptin (2.18), vildagliptin (2.19), saxagliptin (2.20)) for treating type 2 
diabetes (Fig. 2.5). Long-term use of GLP-1 receptor agonists are increasing glycaemic 
control in patients with type 2 diabetes with a very low risk of hypoglycaemia. Nausea is a 




                                                  Liraglutide 2.16 
 
H-His-Gly-Glu-Gly-xiThr-Phe-xiThr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Ala-Val-
Arg-Leu-Phe-xille-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2                  
                                                 Exenatide 2.17 


































Figure 2.5.  Chemical structures of GLP-1 and DPP-4 agents used for type 2 diabetes. 
2.3.8 Amylin Agonists 
Amylin, an islet amyloid polypeptide, or IAPP, is a 37-amino acid peptide hormone. It is 
co-stored and co-secreted with insulin and uses similar processing enzymes.43 Adults with 
type 1 diabetes have no amylin, while those with type 2 diabetes have a relative deficiency 
in later stages of the disease.44 Since the insoluble amylin is toxic to pancreatic beta cells, 
the discovery of a soluble amylin agonist was considered as a new diabetes medication. 
Pramlintide (2.21) (Fig. 2.6) is a synthetic analogue of amylin and it was approved by the 
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2.3.9 Bromocriptine 
Bromocriptine (Cycloset®) (2.22), a sympatholytic D2-dopamine receptor agonist, has 
been approved to treat patients with type 2 diabetes (Fig. 2.7).45 Yet, its mechanism is not 
clear but based on some studies, it is believed that bromocriptine can increase dopamine 
activity in the brain. Since it is not possible to sample the human brain, all the hypotheses 
on the bromocriptine mechanism of action have been derived from animal experiments. 
Bromocriptine causes a reduction in glycated haemoglobin and lessens plasma triglyceride 
and the concentration of free fatty acids, whether it was used as monotherapy or in 
combination with other hypoglycaemic agents.45 The benefits of Cycloset® include the 


















Bromocriptine 2.22  
Figure 2.7. Chemical structure of bromocriptine. 
2.3.10 Colesevelam 
Colesevelam hydrochloride (2.23) is a polymer formed from allylamine which was 
crosslinked with epichlorohydrin and alkylated with 1-bromodecane and (6-bromohexyl) 
trimethylammonium bromide and has an approximate molecular weight of 1014 Dalton 
(Fig. 2.8). It is a lipid-lowering agent and is used to reduce elevated low-density lipoprotein 
cholesterol in patients.46 However, it was also approved in 2008 by the USFDA to treat 
type 2 diabetes.31 Results from a clinical trial suggest that the antidiabetic mechanism of 
colesevelam involves an increase in incretin secretion and improved β-cell function, but 
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Figure 2.8. Formation of colesvelam hydrochloride. 
 
To conclude, there are many types and classes of available medication for the treatment of 
diabetes mellitus. The main goal of all these medications is to adjust blood glucose levels. 
These medications achieve this goal in different ways. In some cases, there is a need to 
combine more than one type of these drugs to target multiple processes that could possibly 
affect glucose levels in the blood. However, the major disadvantages of these drugs are the 
side effects, especially in the long term and the cost of the treatments. There is an 
opportunity to develop natural products in a scientific way to discover new active 
compounds that have less or no side effects and at the same time are affordable to people 
worldwide living under the poverty threshold. 
 
 
16 | P a g e  
 
2.4 MEDICINAL PLANTS USED FOR TREATMENT OF DIABETES 
2.4.1 Introduction 
Natural products from different sources, especially from plants, have long been used as 
remedies for human diseases and it will always remain a potential source of future drugs.48 
Many of the current drugs have been derived directly or indirectly from plant sources. In 
this context, out of 250 000 plants, approximately 1% have been tested pharmacologically 
and a much smaller number assayed against diabetes mellitus.49 Reports on ethnobotany 
indicate that there are at least 800 plant species that could have antidiabetic potential. 
Amongst these plants, Pterocarpus marsupium (Fabaceae), Momordica charantia 
(Cucurbitaceae), and Trigonella foenum greacum (Fabaceae) are found to be beneficial for 
the treatment of type 2 diabetes.50 
 
Recently, a review article considered all of the in vivo antidiabetic studies conducted 
between January 2000 to July 2013 on African plants and reported that the most 
investigated plant families are Asteraceae and Lamiaceae.51 Moreover, while many studies 
reported promising findings, in only a few investigations the bioactive components have 
been identified and characterized and their mechanisms of action investigated.51 In the next 
paragraph, the active principles of South African plants with antidiabetic properties are 
discussed. 
2.4.2 Medicinal plants with antidiabetic properties used in South Africa 
Plants with antidiabetic properties in South Africa have been extensively reviewed in the 
last decade.51,52,53 Many plant species such as Vernonia amygdalina Del, Leonotis leonurus 
L. (Lamiaceae), Aloe ferox, Aloe greatheadii, and Brachylaena discolor have been tested 
for antidiabetic properties by investigating the bioactivity in the extracts of the leaves, 
flowers, roots, and sometimes the whole plant.54,55,56 Table 2.2 summarized the available 
literature of medicinal plants with antidiabetic properties used in South Africa.
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Table 2.2. The in vitro and in vivo antidiabetic effects of some South African medicinal 
plants and the identification of the bioactive compounds. 
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(Lam.) Kuntze ex 
Thell. (Asteraceae) 
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Aloe vera (L.) Burm.f. (Asphodelaceae) (synonym A. barbadensis) is an African plant that 
has been used traditionally to treat diabetes.94 In order to confirm the antidiabetic properties 
of the plant, Tanaka et al.59 evaluated its antihyperglycaemic effect and isolated five active 
compounds. These compounds were identified as cycloartanol (2.24), 24-
methylenecycloartanol (2.25), lophenol (2.26), 24-methyllopenol (2.27), and 24-
ethyllophenol (2.28) (Fig. 2.8). These compounds showed a significant reduction in blood 




Figure 2.9 Chemical structures of antidiabetic compounds isolated from Aloe 
barbadensis Mill. 
 
Aspalathus linearis (Fabaceae) is an indigenous South African plant, commonly known as 
rooibos. Rooibos herbal tea has become popular worldwide.95 An investigation of rooibos 
shoots extract (rooibos tea) on streptozotocin-induced diabetic rats demonstrate a 
hypoglycaemic effect by reducing blood glucose in diabetic rats over a 6 hour period.64 
These findings led to other studies in which the active compounds of A. linearis were 
identified as Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid (2.29) and 2-oxo-3-
phenylpropanoic acid (2.30) (Fig .2.10). These two compounds isolated from A. linearis 
increase the in vitro glucose uptake in Chang liver cells and improve glucose tolerance in 
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an insulin-resistant rat model.63 Other active compounds, such as aspalathin (2.31), 
nothofagin (2.32), and rutin (2.33) (Fig. 2.10), which showed potential as new agents that 
can contribute to diabetes therapy, were also isolated from A. linearis.64,65 Recently, it was 
reported that aspalathin (2.31) isolated from green rooibos extracts promoted the uptake of 
glucose in cells but that the effect was less than the effect of the crude extract.66 
 
Figure 2.10  Chemical structures of antidiabetic compounds isolated from Aspalathus 
linearis. 
 
Cyclopia species are native South African plants and Cyclopia intermedia (Fabaceae) is 
commonly known as honeybush tea. The honeybush tea prepared from C. intermedia has 
no caffeine, little tannin and other health benefits including antidiabetic properties.96 The 
hot water extract of honeybush was found to be effective in reducing blood glucose levels 
in induced diabetic rat models. The antidiabetic properties were mainly attributed to the 
presence of phenolic compounds 2.34-2.40 (Fig. 2.11).69 
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Figure 2.11 Chemical structures of phenolic compounds isolated from Cyclopia intermedia 
 
Other Cyclopia species such as C. maculata and C. subternata were also investigated to 
evaluate their potential to treat different diseases such as anti-obesity and antidiabetic 
properties.70,71 It is known that diabetes is associated with atherosclerotic and inflammatory 
diseases leading to cardiovascular complications.97 Ku and Bae70 showed that the 
flavonoids vicenin-2 (2.41) and scolymoside (2.42) (Fig. 2.12), reduced high-glucose-
induced vascular inflammatory diseases in human endothelial cells and in mice. Therefore, 
honeybush may be able to diminish atherosclerosis as a complication of diabetes. 
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Deutschländer et al.72 investigated the hypoglycaemic activity of Euclea undulata Thunb. 
(Ebenaceae), a plant traditionally used to treat diabetes by South African healers. The 
screening of the acetone and ethanol extracts of the root and stem bark scientifically 
confirmed the traditional use of E. undulata for treatment of diabetes. Further 
investigations by Deutschländer et al.74 yielded four antidiabetec compounds. Amyrin 3-
O-β-(5-hydroxyferulate) (2.43), betulin (2.44), lupeol (2.45), and epicatechin (2.46) were 


























Epicatechin (2.46)  
Figure 2.13. Chemical structures of antidiabetic compounds isolated from Euclea 
undulata  
Leaves and flowers of Leonotis leonurus L. (Lamiaceae) were also used traditionally for 
the treatment of diabetes and hypertension in South Africa.105,106 The aqueous extract of 
the leaves showed hypoglycaemic effects in streptozotocin-induced diabetes in mice, by 
reducing the blood glucose.106 Antidiabetic activities of L. leonurus were attributed to the 
different flavonoids, diterpenoids, and polyphenolics (Table 2.1).107 Some of the isolated 
chemical components from L. leonurus are shown in Fig 2.14. 
 
 














Marrubiin (2.48)  
Figure 2.14.  Chemical structures of antidiabetic compounds isolated from Leonotis 
leonurus. 
Momordica charantia L., known as bitter gourd, was used traditionally by native people of 
Asia, America, India, the Caribbean islands, and Africa to treat diabetes. M. charantia was 
subjected to several animal model and biochemical studies to prove the antidiabetic effects 
that were known to the traditional healers. The isolated compounds such as sitosteryl 
glucoside (2.49), stigmasteryl glucoside (2.50), vicine (2.51) (Fig. 2.15), and polypeptide-







































Figure 2.15. Chemical structures of antidiabetic compounds isolated from Momordica 
charantia 
Banana (Musa sp. var. Nanjangud rasa bale), is a common cultivated plant worldwide, 
mainly for the high nutritional value of its fruit. Banana flowers can be used as a vegetable 
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and it has been traditionally recommended by the Indian herbalists for diabetes.99 An in 
vivo antidiabetic assessment of banana flowers in a hyperglycaemic rodent model by Ramu 
et al.100 reported that banana flower extract and its constituents umbelliferone (2.52) and 
lupeol (2.45) (Fig. 2.16) enhanced the glycolysis reaction and significantly increased the 
utilization of glucose in diabetic rats. 
 
 
Figure 2.16. Chemical structures of antidiabetic compounds isolated from Musa sp. 
 
Psidium guajava L. (Myrtaceae) is not an indigenous South African plant, but it has been 
widely used, locally to treat diabetes. The hypoglycaemic activity of P. guajava organic 
extract of the leaves and the organic and aqueous extracts of the roots were found to be 
active in fat and muscle cells.52 Another investigation of the hypoglycaemic and 
hypotensive effects of the aqueous extract of P. guajava leaves caused dose-related 
hypoglycaemia in normal and streptozotocin-induced diabetic rats. The hypoglycaemic 
effects of the aqueous extract of P. guajava leaves were speculated to be as a result of the 
presence of tannins, flavonoids, pentacyclic triterpenoids, guiajaverin (2.53), quercetrin 















Guiajaverin (2.53)       R=L-arabinose












Figure 2.17. Chemical structures of antidiabetic compounds isolated from 
Psidium guajava 
 
Sclerocarya birrea Rich. Hochst. (Anacardiaceae) is one of the common plants used 
traditionally to treat diabetes in South Africa. The stem-bark organic extract 
(dichloromethane:methanol, 1:1) of S. birrea was found to increase the glucose utilization 
in Chang liver and C2C12 muscle cells.52 In support, Dimo et al.101 reported that the organic 
extract of S. birrea bark decreased blood glucose and increased plasma insulin levels in 
streptozotocin rats. Different classes of chemical compounds have been isolated from S. 
birrea including flavonoids, alkaloids, triterpenoids, coumarins, ascorbic acid and amino 
acids.84,102  
 
Sutherlandia frutescens (L.) R. Br. (Fabaceae) is commonly used by many cultural groups 
for different diseases such as peptic ulcer, cancer, heart failure, and diabetes.90,91 S. 
frutescens aqueous extract was assayed in human liver cells and was found to prevent 
insulin resistance.91 Chemical compounds isolated from S. frutescens include pinitol (2.56), 
triterpenoid saponins, flavonoids, and amino acids.90 Pinitol (2.56) is a well-known 
antidiabetic agent which has the same properties as insulin.103 The chemical structure of 












Pinitol (2.56)  
Figure 2.18. Chemical structure of an antidiabetic compound isolated from 
Sutherlandia frutescens 
 
Terminalia sericea Burch.ex DC. (Combretaceae) is an indigenous southern African plant 
that has been widely used to treat different diseases and illness such as stomach problems, 
bilharzia, pneumonia, and diabetes.104 The most common chemical constituents are stilbene 
glycosides and phenolic compounds. An acetone stem bark extract of T. sericea led to the 
isolation of four compounds, β-sitosterol (2.57), β-sitosterol 3-acetate (2.58), lupeol (2.45), 
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A phytochemical analysis of the leave extract of Vernonia amygdalina Del. confirms the 
claimed ethnomedicinal uses of the leaves of V. amygdalina to treat different infectious 
diseases.55 Erasto et al.93 studied the effect of the leaf water extract of V. amygdalina on 
glucose utilization in C2C12 muscle, 3T3-L1 and Chang liver cells. Their results showed 
that the water extract significantly increased glucose utilization in Chang liver and C2C12 




In conclusion, although large numbers of plants have been traditionally used to treat 
different diseases, only limited numbers of these plants have been scientifically 
investigated. In South Africa, while there are at least 73 plants traditionally used for 
diabetes treatments,108 only a few plants were investigated for their antidiabetic activity 
(Table 2.2). The enhancement of the traditional experience to treat diabetes with original 
research could potentially discover a new safe and cheap drug. 
 
 
31 | P a g e  
 
CHAPTER 3: BRACHYLAENA DISCOLOR: TAXONOMY, 
PHYTOCHEMISTRY AND ANTIDIABETIC ACTIVITY 
 
3.1 INTRODUCTION 
For many centuries, several plant species from different families have been used 
traditionally for the management of the glucose level in human blood. Globally, about 800 
plants are reported to have antidiabetic potential.109 Out of these plants, only a few have 
been evaluated using sophisticated methods to investigate their efficacy in the treatment of 
diabetes. For example, some plants such as Artemisia afra Jacq. ex Willd., Leonotis 
leonurus (L.) R.Br.  and Catharanthus roseus (L.) have been evaluated for their potential 
to treat diabetes in animals.53 While research has been done on some plant species for their 
antidiabetic properties, little work was conducted on Brachylaena discolor. This study 
focuses on B. discolor, a member of the Asteraceae family. 
3.2 AN OVERVIEW OF BRACHYLAENA 
3.2.1 Asteraceae family 
The Asteraceae is one of the major plant families, consisting of herbs, shrubs, and trees 
with more than 1620 genera and 23 600 species distributed worldwide.110 The stems are 
usually vertical and in some species are prostrate to ascending. The leaves are generally 
alternate or opposite and sometimes in basal rosettes. The Asteraceae is commonly found 
in the arid and semiarid climate areas of the subtropics.111 Asteraceae plants are a source of 
several active compounds such as essential oils, polyphenolic compounds, flavonoids, 
terpenoids, phenolic acids, alkaloids, lignans, saponins, stilbenes, sterols, and 
polysaccharides. Some species of this family are commonly used to treat different diseases 
like HIV and cancer.112  
3.2.2 Phytochemistry of Asteraceae 
Asteraceae is a plant family rich in chemicals that have biological activity and have  
potential for development of new drugs.113 Sesquiterpene lactones are secondary 
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metabolites and a large class of natural compounds (over 5000 known compounds) that 
have been obtained from different plant families (e.g. Acanthaceae, Asteraceae, 
Anacardiaceae, Lauraceae, Apiaceae, Euphorbiaceae, Winteraceae, and Hepatideae).114,115 
According to Ohnishi et al.,116 the highest number of sesquiterpene lactones were isolated 
from the Asteraceae, with about 3000 different structures.  
3.2.3 Brachylaena genus 
There are fifteen species/subspecies of Brachylaena R. Brown in eastern and southern 
Africa and Madagascar. In South Africa, there are nine species. The name Brachylaena is 
derived from the Greek words meaning shorter and cloak, which refers to the flowers being 
longer than the involucre.117 Based on the pollen morphology, the southern African species 
could be categorized into two groups; group one includes B. huillensis O.Hoffm. and B. 
ilicifolia (Lam.) E.Phillips & Schweick., and group two includes B. discolor DC., B. 
elliptica (Thunb.) DC., B. glabra (L.f.) Druce, B. neriifolia (L.) R.Br., B. rotundata 
S.Moore, B. transvaalensis E.Phillips & Schweick., and  B. uniflora Harv.118,119 
Sesquiterpene lactones occur widely in the Asteraceae family and have also been isolated 
from Brachylaena species. Sesquiterpene lactones are mostly colourless lipophilic 
compounds.120 Sesquiterpene lactones are terpenoids that naturally occur in plants and 
represent a large and unique chemical class of compounds which have a 15 carbon chain 
formed by three isoprene units with subsequent enzyme-mediated cyclization and oxidative 
transformation to produce cis or trans-fused lactones. The large number of sesquiterpenes 
can be attributed to the fact that one synthase may produce many sesquiterpene products.121 
Sesquiterpenes are further classified based on their carbocyclic skeletons into 
pseudoguaianolides (3.1), guaianolides (3.2), germanocranolides (3.3), eudesmanolides 
































Hyptocretenolides (3.6)  
Figure 3.1. The basic carbocyclic skeletons of different types of sesquiterpene 
lactones. 
Health benefits of sesquiterpene lactones have been studied due to their various biological 
activities.120,123 These studies focussed on the use of sesquiterpene lactones against a wide 
range of diseases. For example, some studies investigated their potential as anticancer, 
antitumour, anti-ulcer, anti-inflammatory, neurocytotoxic, and cardiotonic drugs.124,120 
Others studies focused on their uses as antimalarials, antimigraine activity and prevention 
of neurodegeneration, analgesic, and sedative activities and treating diarrhoea, flu, and 
burns.125,120,126 The active sesquiterpene lactones isolated from different plants that showed 
potential to treat cancer, inflammation, and malaria will be briefly highlighted in the next 
section. 
In general, 60% of all anticancer drugs were originally derived from natural products.127 
The structures of some sesquiterpenes lactones with in vitro cytotoxicity towards cancer 
cells are given in Fig. 3.2. Costunolide (3.7) and dehydrocostuslactone (3.8) are the most 
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well-known sesquiterpene lactones with anticancer properties. These compounds were 
isolated from plant species such as Saussurea lappa Decne and Laurus nobilis L.128 The 
mechanisms of these compounds as anticancer agents were attributed to several pathways 
such as inhibition of growth of new cancer cells, angiogenesis, and reducing secondary 
malignancy. Their mechanisms also include differentional induction, regulation of new 
cancer cell cycle and reversal of the drug resistance of cancer cells.128 
Arglabin (3.9), another active compound that is classified as a guaianolide, was isolated 
from Artemisia glabella and was found to have potential for treatment of cancer-related 
malignancies such as breast, colon, ovarian, and lung cancers.129 Micheliolide (3.10), also 
a member of the guaianolides, was isolated from Michelia compressa and Michelia 
champaca.130,131 Micheliolide (3.10) has shown high efficiency in treating leukaemia in 
mouse models. Other sesquiterpene lactones like parthenolide (3.11) and helenalin (3.12) 
isolated from different medicinal plants have anticancer and anti-inflammatory properties. 
 
Figure 3.2.  Structures of sesquiterpene lactones with anticancer activity. 
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The structures of some sesquiterpene lactones with anti-inflammatory activity are given in 
Fig. 3.3. Parthenolide (3.11), a sesquiterpene lactone isolated from Tanacetum parthenium 
(L.) Sch. Bip., a plant commonly known as “Feverfew”, showed direct inhibition of pro-
inflammatory enzymes such as phosphodiesterase-3, phosphodiesterase-4, and 5-
lipoxygenase.132 Helenalin (3.12) and dihydrohelenalin (3.13) were isolated from A. 
montana flower extracts and the proportions of each compound (helenalin (3.12) and 
dihydrohelenalin (3.13)) and their anti-inflammatory efficacy was reported to vary over the 
geographical range of A. montana.133 Cynaropicrin (3.14) is a sesquiterpene lactone 
isolated from the roots of Saussurea lappa.124 Cynaropicrin (3.14) was found to inhibit 
TNF-α and NO production, suggesting that the compound has anti-inflammatory 
properties. Finally, isoalantolactone (3.15) and alantolactone (3.16), major bioactive 
ingredients found in many medicinal plants (e.g. Inula racemose, Inula helenium, 




Figure 3.3. Structures of sesquiterpene lactones with anti-inflammatory activity. 
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After the malaria parasite became resistant to the quinoline-based drugs (e.g. chloroquine 
and pyrimethamine), new antimalarial drugs needed to be developed. Artemisinin (3.17), a 
natural product isolated from the leaves of Artemisia annua L. (Asteraceae), was found to 
be effective in killing malaria parasites.136 The structures of some sesquiterpenoids with 
antimalarial activity are given in Fig. 3.4.  
Three antimalarial active compounds, namely 8α-tigloyloxyhirsutinolide 13-O-acetate 
(3.18), 8α-(4-hydroxymethacryloyloxy)hirsutinolide 13-O-acetate (3.19), and vernolide D 
(3.20) were isolated from an extract of Vernonia cinereal.125 Lactucin (3.21) and 
lactucopicrin (3.22) are also antimalarial compounds that were isolated from the roots of 
Cichorium intybus L.137 Kraft et al.138 isolated four sesquiterpenes (vernodalol (3.23), 
dihydrovernodalin (3.24), 11β,13-dihydrovernolide (3.25), and 11β,13,17,18- 












8-Tigloyloxyhirsutinolide 13-O-acetate (3.18):  R1=A, R2=Ac
8-(4-Hydroxymethacryloyloxy)hirsutinolide 13-O-acetate: (3.19) R=B, R1=Ac




































Figure 3.4. Structures of sesquiterpene lactones with antimalarial activity. 
Natural products provide a vital antiviral drug source and the mechanisms of these natural 
agents generally, is targeting the life cycle of the virus and the interactions between the 
virus and the specific host.139,122 Some sesquiterpene lactones such as artemisinin (3.17) 
and its derivative artesunate (3.27), isolated from Artemisia annua L., showed good 
antiviral activity including the human cytomegalovirus, Herpesviridae family, hepatitis B 
& C virus and bovine diarrhoea virus.139 Hwang et al.140 tested several sesquiterpene 
lactones such as costunolide (3.7), parthenolide (3.11), helenalin (3.12), alantolactone 
(3.16), artemisinin (3.17), dehydrocostuslactone (3.28), epoxy-(4,5α)-4,5- dihydrosantonin 
(3.29), and 1,2-epoxy-1,2-dihydrosantonin (3.30) against hepatitis C virus. Their results 
showed that helenalin (3.12) was the best anti-hepatitis C viral compound. The structures 
of these antiviral compounds are given in Fig. 3.5. 
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Figure 3.5. Structures of sesquiterpene lactones with antiviral activity. 
There has been strong evidence indicating that some of the sesquiterpene lactone 
compounds have antibacterial and antifungal activity.122,141 Most of the sesquiterpene 
lactones biological activities were attributed to the presence of 𝛼-methylene-𝛾-lactone in 
their structure, which exerts its effect by the alkylation of thiol groups found in proteins.141 
The most common antibacterial sesquiterpene lactones are vernodalin (3.34) and vernolide 
(3.35), which were isolated from different plants (e.g. Vernonia colorata and Vernonia 
amygdalina).55,142 6-O-Methylacrylylplenolin (3.31), 6-O-angeloylplenolin (3.32), 6-O-
isobutyroylplenolin (3.33), and other sesquiterpene lactones isolated from Centipeda 
minima, showed high antibacterial activity when they were screened against Bacillus 
subtilis and Staphylococcus aureus.143 
The antifungal activity of sesquiterpene lactones were also confirmed in several studies 
worldwide.122,144,120 There are many antifungal compounds isolated from different plant 
species. For example, isoalantolactone (3.15) and elema-1,3,11-trien-8,12-olide (3.36), 
were isolated from Ratibida mexicana, while 8α-hydroxy-4-epi-sonchucarpolide (3.37) and 
8α-(4-acetoxy-3-hydroxy-2-methylenebutanoyloxy) (3.38) were isolated from Centaurea 
thessala spp. drakiensis and C. attica spp. attica.145 The structures of these compounds are 
given in Fig. 3.6. 
 
 
















































Figure 3.6. Structures of antibacterial and antifungal sesquiterpene lactones. 
3.2.4 Phytochemistry of Brachylaena 
The investigation of the Brachylaena species started in 1982, when sesquiterpene lactones 
and other chemical ingredients such as a guaianolide (3.2), a germacranolide (3.3) and three 
eudesmanolides (3.4) were isolated from the aerial parts of B. transvaalensis and B. 
rotundata.146 The study revealed that these two Brachylaena species have a number of 
chemical compounds such as acetylenic compounds, lupeyl acetate, linoleic  and linolenic 
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acid, germacrene D (3.39), and two germacranolide derivatives, onopordopicrin (3.40) and 
salonitenolide (3.41). 
The aerial parts of B. rotundata was also investigated together with three other Brachylaena 
species (B. nereifolia, B. elliptica, and B. discolor) by the same authors in 1987.147 The 
second investigation of B. rotundata yielded onopordopicrin (3.40) and salonitenolide 
(3.41). In addition, five guaianolide glucopyranosides and three germacranolides were 
isolated from the aerial part of B. nereifolia, while B. elliptica and B. discolor yielded a 
large amount of onopordopicrin (3.40).147,148 
Other guaianolides were isolated from the aerial parts of B. huillensis and B. perrieri. B. 
huillensis produced five compounds, cynaropicrin (3.14), aguerin A (3.42), aguerin B 
(3.43), lupeol (2.45), and its acetate, while B. perrieri yielded only lupeol (2.45) and its 






























































Aguerin A (3.42) Aguerin B (3.43)
 
Figure 3.7. Chemical structures of the components isolated from Brachylaena species 
 
3.2.5  Medicinal uses of Brachylaena in South Africa 
In traditional medicine in South Africa different plants are used to treat a wide range of 
diseases such as stomach illnesses and chronic diseases (heart failure, chronic respiratory, 
and diabetes).52,150 Plants from the Brachylaena genus, which is indigenous to South Africa, 
have been used by the rural communities in South Africa to treat several diseases. In this 
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genus, the leaves of B. transvaalensis, B. discolor, and B. ilicifolia have been used for 
treatment of diarrhoea in humans and animals.150,151,152 DCM-MeOH and aqueous extracts 
were used to evaluate the antimicrobial activity of B. transvaalensis.153 Antimicrobial 
activity was observed for the combination of B. transvaalensis with other plants species 
such as P. guajava. 
An in vitro anticancer screening of 7500 South African plants against three human cancer 
cell lines showed that DCM leaves extract of Brachylaena rotundata S. Moore has activity 
against cancer cell lines and the highest number of plants assayed were from the Asteraceae 
family.154 The cytotoxic activity in B. rotundata could probably be attributed to the high 
concentration of sesquiterpene lactone compounds. Sesquiterpene lactones were found to 
increase cancer cell deaths by decreasing glutathione levels.130 
In the Brachylaena genus, there are only three species that have been used traditionally for 
the treatments of diabetes, namely B. elliptica, B. ilicifolia, and B. discolor. The leaves of 
B. elliptica were traditionally used by Zulu and Xhosa tribes as an antidiabetic treatment.155 
The ethnomedicinal uses of B. elliptica and B. ilicifolia leaves to treat diabetes were 
attributed to the existence of antioxidant compounds (e.g. flavonoids, phenols, alkaloids, 
saponins, tannins, and other compounds).156 Deutschländer et al.155 reported that B. discolor 
is one of the plants that is used by indigenous people in South Africa to treat diabetes, renal 
problems and used as a tonic. Van de Venter et al.52 conducted an antidiabetic screening 
against Chang liver, 3T3-L1 adipose, and C2C12 muscle cells of 11 South African plants. 
They found that B. discolor had the best results in term of activity scores and low toxicity. 
The compounds that have been previously isolated from the aerial parts of B. discolor were 
onopordopicrin (3.40) and lupeyl acetate (3.44)157,147 
 
3.2.6 Brachylaena discolor 
B. discolor is a shrub or small tree that grows naturally on the coastal dunes of the eastern 
part of South Africa and also occurs in Mozambique and Zimbabwe. It is commonly known 
as coast silver oak (English), kusvaalbos (Afrikaans), and iphahla, umpahla (isiZulu).158 
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It is an evergreen shrub or small tree, usually 4 to 10 m in height. Leaves are 5–11 cm long, 
dark green above, with distinctive silvery-grey undersides (Fig. 3.8). Flowers are creamy-
white and arranged in dense terminal panicles. The tiny seeds are tipped with tufts of 
yellowish hairs. The plant is evergreen with a dark grey rough bark. The leaves are 
lanceolate with a dark green colour on the top and is pale whitish below, with both sides 
covered with dense hairs. B. discolor has small achene fruits covered with tufts of bristly 
hairs.159,160 The distribution map of B. discolor is given in Fig. 3.8. 
 
 
Figure 3.8. Locations where B. discolor (both types) have been collected in Africa 
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3.3 RESULTS AND DISCUSSIONS  
3.3.1 Extraction and biological assay 
In a previous investigation by Van de Venter et al.,52 a number of plant extracts were 
assayed for antidiabetic activity and B. discolor was identified as one of the active plants.52 
These authors found that all plant parts of the plants were active. No cytotoxicity was 
observed for the extracts. Although the photochemistry of B. discolor has been investigated 
by Zdero and Bohlmann,147 the active compound(s) present in B. discolor have not been 
identified. 
In this investigation, we revisited the phytochemistry and activity of the leaves of B. 
discolor. Plant material of B. discolor was collected at the UKZN Botanical Garden in 
Pietermaritzburg. The leaves were dried, milled, and extracted with DCM-MeOH (1:1). 
Before analysing for activity, the crude extract was fractionated into five fractions by using 
a Diol SPE column (2 g/6 mL) (Table 3.4). This procedure was used to separate the polar 
fraction containing mostly tannins and carbohydrates from the medium polar compounds, 
which are often associated with biological activity. Diol is a stationary phase in which the 
silica is derivatised with 1,2-dihydroxypropane and can be used with a wide range of 
compounds. It is compatible with a wide range of the solvents, from hexane to water, and 
using the SPE columns is a reliable method to fractionate a crude extract into sub-fractions 
of different polarities which can be assayed for activity.161 
The crude extract and the five fractions obtained from the Diol column were assayed in an 
in vitro assay where the effect of the different fractions on the glucose utilization on muscle 
cell line (C2C12) was investigated. The results of this experiment are illustrated in Fig 3.9. 
In type 2 diabetes, cells are losing the ability to utilize glucose. Therefore, compounds 
which stimulate the uptake of glucose by the cells (observed by a lower glucose 
concentration in the solution) are considered as potential antidiabetic compounds. As can 
be seen from the results (Fig. 3.9), after 24 h the crude extract (2A) showed a moderate 
effect, but after 48 h a much higher activity was observed. Among the fractions, the highest 
activity was observed for Fractions A and E, both after 24 and 48 h. Both fractions B and 
C showed low antidiabetic activity after 24 h, but fraction C appeared to be more active 
after 48 h.  
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The results of this study confirm the finding by Van de Venter et al.52 using the DCM-
MeOH (1:1) extract of B. discolor against Chang liver, 3T3-L1 adipose, and C2C12 muscle 
cell. Mellem et al.162 also reported that the methanolic leaves extract of B. discolor has high 
α-glucosidase inhibition with little toxicity. However, these two research groups only 
assayed the crude fractions and did not do any further fractionation. Unfortunately, our 
collaborator doing the antidiabetic assays, Prof C. T. Musabayane, passed away during this 
investigation and we were not able to conduct further bioassays. 
 
Figure 3.9. The effects of plant extracts on glucose utilization in muscle cell line after 
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3.3.2 Lupeol acetate and its Δ12 isomer (3.45 and 3.46) 
Fractionation of the crude extract as described in the experimental section, led to the 
isolation of five compounds. Herewith, the structural elucidation of these compounds are 
described. 
Fractionation with a DIOL SPE column is a convenient and reliable method to separate a 
crude extract into fractions of different polarities. However, the SPE columns can only be 
loaded with a small amount of extract (100 mg). To save on costs, we have adapted the 
method to a column chromatography procedure on silica gel for larger amounts of extract 
(see first step in isolation procedure, Fig. 3.14).  
Fraction A (Fig. 3.15) yielded a white needle-like solid, which appeared to be one 
compound on TLC. However, NMR spectroscopy indicated that it consists of a pair of 
inseparable isomeric triterpenes, lupeol acetate [3β-acetoxy-20(29)-lupene] (3.45) and its 
Δ12 isomer, 3β-acetoxy-12-lupene (3.46), also known as neolupenyl acetate.163 
In the 1H NMR spectrum, the following resonances were observed: 
δH 5.26 (br d, H-12, neolupenyl acetate), δH 4.69 (br s, H-29a, lupeol acetate), δH 4.57 (br 
s, H-29b, lupeol acetate), δH 4.49 (m, H-3, lupeol acetate, neolupenyl acetate), δH 2.37 (dt, 
J 10.9 and 5.5 Hz, H-19, lupeol acetate), δH 2.043 (s, OAc (lupeol acetate), 2.037 (s, OAc, 
neolupenyl acetate) 0.79 (s, H-28, lupeol acetate, neolupenyl acetate), 0.73 (s, H-26, lupeol 
acetate, neolupenyl acetate). Unfortunately, when the other spectroscopic data were 
recorded, it was observed that the compounds had decomposed. The NMR data assigned to 
lupeol acetate (3.45) agrees with the shifts reported for the compound by Jamal et al.164 
The high-resolution ESI-(+)-TOF mass spectrum, displayed a M+H ion at 469.4071, 


































The polarity of these two isomeric compounds are similar and it came to no surprise that 
conventional column chromatography could not separate the two compounds. This 
chromatographic behaviour was also observed with two other isomeric triterpenoids, 
arjunolic acid and asiatic acid.165,166 
The two compounds, lupeol acetate (3.44) and its Δ12 isomer (3.45), were also isolated from 
the aerial part of B. discolor by Zdero and Bohlmann.147 However, these authors did not 
disclose any spectroscopic data for the two compounds. Recently, lupeol acetate (3.44) was 
isolated from Pseudobrickellia brasiliensis and its Δ12 isomer (3.45) from Ficus 
sansibarica.167,168  
A number of triterpenes have been identified as promising agents to prevent diabetes 
complications.169,170 Lakshmi et al.171 reported that lupeol acetate (3.44) and its parent 
compound lupeol (2.45) showed in vivo antidiabetic activity comparable to metformin, a 
drug that is clinically used for the treatment of diabetes.172 It was also reported that lupeol 
is a potent inhibitor of the enzyme protein tyrosine phosphatase (PTP1B).172-174 PTB1B 
plays an important role in the inhibition of insulin action, development of Type 2 diabetes 
and obesity. Inhibitors of this enzyme are considered as potential leads for the development 
of new antidiabetic and antiobesity drugs. Lupeol and its derivatives are considered as 
promising candidates in this regard.174,175 
A review on the health effects of lupeol also pointed out that lupeol has several other 
important pharmacological activities.176 Neolupenyl acetate (3.45) is a rare compound in 
nature and there are no reports on its biological activity. Taking the evidence above into 
account, it is most likely that the antidiabetic activity of B. discolour can be attributed to 
the presence of lupeol acetate (3.44) and its Δ12 isomer (3.45). 
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3.3.3 β-Sitosteryl linolenate (3.46)  










The 1H and 13C NMR spectra of β-sitosteryl linolenate (3.46) are shown in Plate 2A and 
Plate 2B, respectively, and the data are collated in Table 3.1. The NMR spectra contained 
features of both a steroid and a fatty acid and initially the sample was considered as a 
mixture of two compounds. However, on careful inspection of the NMR spectra it was 
concluded that the sample consisted of a clean compound containing both fatty acid and 
steroid moieties.  
The fatty acid moiety was identified by an ester carbon resonating at δC 173.3. The 
methylene group alpha to the ester carbon was identified by a long-range 1H,13C correlation 
in the HMBC (Plate 2G) between the signal at δC 173.3 and two protons resonating as a 
triplet at δH 2.26.  In the COSY, the protons at C-2' further coupled with methylene protons 
resonating at δH 1.60. However, this region showed a large overlap of 
1H NMR resonances 
and it was concluded that an extended alkyl chain was attached to the ester. Another feature 
of the 1H NMR spectrum was the presence of seven olefinic proton resonances as an 
overlapping multiplet at δH 5.42-5.48. One of these protons were assigned to the steroid 
moiety (see below), which led to the conclusion that the fatty acid moiety had three double 
bonds. This postulate was confirmed by the presence of seven olefinic methine resonances 
in the 13C NMR spectrum at δC 132.0, 130.3, 128.30, 128.28, 127.7, 127.2, and 122.6. 
One of the most common trienoic fatty acids is linolenic acid [(9Z,12Z,15Z)-octadeca-
9,12,15-trienoic acid], an essential omega-3 fatty acid that is found widely in seeds, nuts, 
and vegetable oils. It was proposed that 3.46 might be an ester of linolenic acid. The 
terminal methyl protons (H-18') resonated as a triplet (J 7.4 Hz) at δH 0.98, which correlated 
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with a methyl carbon resonating at δC 14.3 in the HSQC spectrum (Plate 2E). In the COSY 
spectrum, this methyl signal (δH 0.98) correlated with a multiplet at δH 2.06, which showed 
further correlation with the olefinic proton multiplet at δH 5.42-5.48, thus confirming that 
the ester indeed contained an omega-3 fatty acid. In the HMBC spectrum of 3.46(Plate 2G), 
no correlations were observed between the olefinic protons and olefinic carbons, which 
indicated that the three double bonds were not conjugated. Instead, the olefinic carbon 
resonances showed a correlation with a four-proton triplet resonating at δH 2.26, 
corresponding to two carbons resonating at δC 25.5 and 25.6. These signals were assigned 
to two methylene groups each located between two double bonds, as is present in the 
structure of linolenic acid. Comparison of the NMR data of 3.46 with those of methyl 
linolenate reported by Christie,177 confirmed that 3.46 is an ester of linolenic acid (Table 
3.1). 
In the remaining parts of the NMR spectra there were evidence of six additional methyl 
groups: two methyl singlets at δH 0.68 (δC 11.8) and 1.02 (δC 11.8), three methyl doublets 
that appeared at δH 0.82 (δC 19.8), 0.84 (δC 19.1), and 0.92 (δC 18.8), and a methyl triplet 
at 0.85 (δC 12.0). The 
1H NMR spectrum also showed a proton resonance as a multiplet at 
δH 4.60 (δC 73.7) and an olefinic proton as part of the multiplet at δH 5.42-5.48. These 
spectroscopic features indicate that the remaining part of 3.46 is a steroid. The long-range 
1H,13C correlations observed in the HMBC spectrum confirmed that this steroid is β-
sitosterol. Correlations were observed between the resonance at δH 1.02 (19-Me) and 
resonances at δC 37.0 (C-1), 139.8 (C-5), 50.1 (C-9), and 36.6 (C-10) and also between the 
methyl resonance at 0.68 and the carbon resonances at δC 39.8 (C-12), 42.3, (C-13) 56.7 
(C-14), and 56.1 (C-17). The two geminal methyl groups, Me-26 and Me-27, resonated as 
doublets (J 6.8 Hz) at δH 0.84 and 0.82. The remaining methyl protons (Me-29) was 
observed as a triplet at δH 0.85, in agreement with an ethyl substituent on C-24.  
The NMR data of 3.46 were in good agreement with those reported by Chaturvedula et 
al.178 for β-sitosterol (2.57). However, there was one major difference between the NMR 
data for β-sitosterol and those of 3.46 and that was the chemical shift of H-3. Instead of a 
chemical shift of δH 3.51 as reported for β-sitosterol,
178 H-3 of 3.46 had a chemical shift of 
δH 4.60. This was an indication that the oxygen on C-3 was part of an ester group. 
Therefore, the structure of 3.46 was assigned as β-sitosteryl linolenate. 
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Initial attempts to obtain a mass spectrum by electrospray ionization were not successful. 
By changing the ionisation method to API (atmospheric pressure ionisation), a technique 
suitable for extremely non-polar compounds, a mass spectrum could be obtained for 3.46. 
In the API-(+)-TOF mass spectrum a peak of low intensity was observed at m/z 697, 
corresponding to the sodium adduct of the molecular ion. In a study of the mass 
spectrometry of sterol lipids by Wewer et al.179 a fragment at m/z 397 resulting from the 
cleavage of the C-O bond between C-3 and the ester oxygen, was observed. A fragment 
with m/z 397 was also observed in the mass spectrum of 3.46.  
The isolation of 3.46 from the leaves of B. discolor has not been reported previously. β-
Sitosterol (2.57) is a common plant metabolite and occurs in other plant species such as 
Terminalia sericea and Solanum surattense.92,180 Both these studies linked antidiabetic 
activitiy to β-sitosterol. Although Scifinder listed only twenty-seven references for 
compound 3.46, phytosterol esters of fatty acids occur in several plants.180 As a result of 
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Table 3.1. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectroscopic data for β-
sitosteryl linelonate (3.46) in CDCl3. 
  Chaturvedula et al.
178 Christie177 
 
3.46 β-Sitosterol (2.57) 
Methyl 
linelonate 
C position δC δH δC δC 
1 37.0  37.5  
2 29.7  31.9  
3 73.7 4.60 (1H, m) 72  
4 38.2 2.28 (1H, H-4eq) 42.5  
5 139.8  140.9  
6 122.6 5.42-5.48 121.9  
7 31.9  32.1  
8 31.9  32.1  
9 50.1  50.3  
10 36.6  36.7  
12 39.8 1.99, 1.16 39.9  
13 42.3  42.6  
14 56.7  56.9  
15 24.3  26.3  
16 27.8  28.5  
17 56.1  56.3  
18 11.8 0.68 12.0  
19 19.3 1.02 (3H, s) 19.0  
20 36.2  36.3  
21 18.8 0.92 (3H, d, J 6.6 Hz) 19.2  
22 34.0  34.2  
23 26.1  26.3  
24 45.9  46.1  
25 29.10*  29.4  
26 19.8 0.82 (3H, d, J 6.8 Hz) 20.1  
27 19.1 0.84 (3H, d, J 6.8 Hz) 19.6  
28 23.1  23.3  
29 12.0 0.85 (3H, t, J 7.5 Hz) 12.2  
1' 173.3   174.2 
2' 34.7 2.26 (2H, t, J 7.8 Hz)  34.1 
3' 25.1 1.60 (2H, m)  25.0 
4' 29.21* 1.31   
5' 29.17* 1.31   
6' 29.11* 1.31   
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7' 29.6 1.31  29.6 
8' 27.2 2.06  27.3 
9' 130.3 5.42-5.48  130.2 
10' 127.7 5.42-5.48  127.8 
11' 25.6# 2.81 (2H, t, J 6 Hz)  25.7 
12' 128.30† 5.42-5.48  128.3 
13' 128.28† 5.42-5.48  128.3 
14' 25.5# 2.81 (2H, t, J 6 Hz)  25.6 
15' 127.2 5.42-5.48  127.2 
16' 132.0 5.42-5.48  131.9 
17' 20.6 2.06 (2H, m)  20.6 
18' 14.3 0.98, (3H, t, J 7.4 Hz)  14.3 
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3.3.4 α-Tocopherol (3.47) 
The NMR data of compound 3.47 are collated in Table 3.2. In the 1H NMR spectrum of 
3.47 (Plate 3A) there were only a few well-resolved signals. The 13C NMR spectrum (Plate 
3B) indicated the presence of 29 carbon atoms. A prominent feature in the 13C NMR 
spectrum of 3.47 was the evidence of six aromatic carbon atoms without any attached 
protons. The chemical shifts of two of the carbons (δC 145.6 and 144.5) indicated that 
oxygens are attached to these carbon atoms. In the 1H NMR spectrum, three methyl groups 
were observed at δH 2.16 (3H) and 2.11 (6H). The chemical shifts of the methyl protons 
indicated that these groups were attached to the aromatic ring. In the HMBC spectrum of 
3.47 (Plate 3E), long-range 1H,13C-correlations were observed between the methyl protons 
and the aromatic carbons atoms, as indicted in Table 3.2. It was clear that compound 3.47 
contains a fully-substituted benzene ring with three methyl groups, two oxygen 
substituents, and an alkyl substituent attached to it. 
In the 1H NMR spectrum, a two-proton triplet was observed at δH 2.60 that correlated with 
the carbon resonance at δC 20.8 in the HSQC spectrum (Plate 3G). In the COSY spectrum 
(Plate 3D), these protons are correlated with a pair of doublets of triplets with chemical 
shifts at δH 1.81 and 1.75. The HSQC spectrum (Plate 3G) showed that the last-mentioned 
pair of protons are attached to a methylene carbon resonating at δC 31.6. The coupling 
pattern of these protons indicated that they are in a ring where free rotation is not possible. 
In the HMBC spectrum, the methylene protons resonating at δH 2.60 (H-4) correlated to the 
carbon resonances at δC 145.6 (C-10), 117.4 (C-9), 74.5 (C-2) and 31.6 (C-3), whereas the 
two methylene protons resonances at δH 1.81 and 1.75 (H-3) showed long-rang correlations 
to an aromatic carbon resonating at δC 117.4 (C-9), an oxygen-containing carbon resonating 
at δC 74.5 (C-2), two methylene carbons at δC 39.8 (C-1') and 20.8 (C-4) and a methyl 
carbon resonating at δC 23.8 (2-CH3). The NMR data discussed above enabled us to assign 
a chromane substructure for 3.47. The long-range couplings observed in the HMBC 















































Figure 3.10.  HMBC correlations in compound (3.47). 
In the 1H NMR spectrum, the only other discernible feature was the presence of four methyl 
groups resonating as doublets at δH 0.87 (6H), 0.84 (3H), 0.86 (3H). Several methine and 
methylene protons were observed in the spectrum as broad, non-resolved resonances. In 
the HMBC spectrum, the two methyl group protons at δH 0.87 showed long-range coupling 
to the methyl carbons at δC 22.6 and 22.7, indicating the presence of an isopropyl group. 
These methyl protons (δH 0.87) also showed long-range coupling to the methylene carbon 
resonating at δC 24.4. 
Each of the two remaining methyl group protons showed long-range 1H,13C couplings to 
two methylene carbons and one methine carbon. The only unaccounted carbons in the 13C 
NMR spectrum are three methylene carbons. Based on biogenetic considerations, we then 
proposed a substructure containing a saturated linear sesquiterpene (Fig. 3.11). 
H2CR  
Figure 3.11. Substructure based on a saturated linear sesquiterpene. 
This substructure accommodated all the long-range correlations observed in the HMBC 
spectrum. The NMR data of this aliphatic chain is in close agreement with that assigned to 
phytol (Fig 3.12).181  
 
 
Figure 3.12. The structure of phytol 
Connecting the two sub fragments enabled us to assign the structure of compound 3.47 as 
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α-tocopherol was not available to us.182 However, the NMR chemical shifts of the side 
chain is in good agreement with that of phytol, whereas the chemical shifts of the chromane 
moiety is in agreement with the values reported for α-tocopherol.181 
The high-resolution ESI-(-)-TOF mass spectrum confirmed the molecular formula of α-
tocopherol (3.47). A molecular ion was observed at 429.3737 [M-H]-, which agreed with 








-Tocopherol (3.47)  
α-Tocopherol (3.47) or vitamin E was isolated (fraction B) for the first time from B. 
discolor leaves. Jamalan et al.183 reported that α-tocopherol is a well-known antioxidant 
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Table 3.2. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectroscopic data for α-






C position δC   δH COSY GHMBC 
2 74.5 C 
   
2-CH3 23.8 CH3 1.23 (3H, s) 
 
C-1',2,3 
3 31.6 CH2 1.81 (1H, dt, J 13.4 ,7.0 Hz) 
1.75 (1H, dt, J 13.4 ,7.0 Hz) 
H-4 C-1',2,2-CH3,4,9 
C-1',2,2-CH3,4,9 
   
4 20.8 CH2 2.60 (2H, t, J 7.0 Hz) H-3 C-2,3, 9,10 
5 118.5 C 
   
5-CH3 11.3 CH3 2.11 (3H, s) 
 
C-6,9 
6 144.5 C 
   
7 121.0 C 
   
8 122.6 C 
   
8-CH3 11.8 CH3 2.11 (3H, s) 
 
C-7,10 
9 117.4 C 
  
C-10 
10 145.6 C 
   
1' 39.8 CH2 1.53 (2H, m) 
  
3' 37.5 CH2 1.25 (2H, m) 
  
4' 32.7 CH 1.37 (2H, m) 
  
4'-CH3 19.7 CH3 0.85 (3H, d, J 6.7 Hz) 
 
C-3',4',5' 
5' 37.4 CH2 1.25 (2H, m) 
  
6' 24.8 CH2 1.27 (2H, m) 
  
7' 37.5 CH2 1.25 (2H, m) 
  
7'-CH3 12.2 CH3 2.16 (3H, s) 
 
C-6,8 
8' 32.8 CH 1.37 (2H, m) 
  
8'-CH3 19.6 CH3 0.84 (3H, d, J 6.7 Hz) 
 
C-7',8',9' 
9' 37.3 CH2 1.06 (2H, m) 
  
10' 24.4 CH2 1.18 (2H, m) 
  
11' 39.4 CH2 1.13 (2H, m) 
  
12' 28.0 CH 1.51 (1H, m) 
  
12'a-CH3 22.7 CH3 0.87 (3H, d) H-12' C-11',12',12'b-CH3 
12'b-CH3 22.6 CH3 0.87 (3H, d) H-12' C-11',12',12'a-CH3 
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3.3.5 Genkwanin 5-O-β-primeveroside (3.48) 
In the high-resolution mass spectrum of 3.48 (ESI-(-)-TOF), an ion was observed at 
557.1554, corresponding to a formula of C27H29O14 (calc. 577.1557), thereby confirming 
the molecular formula of C27H30O14. 
 
The elucidation of the structure of compound 3.48 was based on NMR spectroscopic data 
(Table 3.3). In the 1H NMR spectrum (Plate 4A), several signals were observed in the 
aromatic region of the spectrum. Two two-proton doublets resonating at δH 7.88 (J 8.8 Hz) 
and 6.94 (J 8.8 Hz) were characteristic of a para-substituted benzene ring, with one 
substituent being an oxygen. Two one-proton doublets at δH 6.97 (J 2.4 Hz) and 6.95 (J 2.4 
Hz) indicated the presence of two meta-coupled protons in a phloroglucinol derivative. 
Additionally, a one-proton singlet was observed at δH 6.63 and a three-proton singlet at δH 
3.96. These data are consistent with a flavone that is substituted on C-5, 7, and 4'. 
 
The 13C NMR spectrum (Plate 4B) was in agreement with a flavone structure. A conjugated 
ketone carbon resonance was observed at δC 180.3 (C-4), in addition to five oxygen-
containing sp2-carbons at δC 166.1, 164.6, 162.9, 160.7, and 159.6, two two-carbon CH 
resonances at δC 129.4 (C-2',6') and 117.1 (C-3',5'), non-protonated carbon resonances at 
δC 122.9 (C-1') and 110.4 (C-4a), and three CH resonances at δC 106.8 (C-3), 104.4 (C-6), 
and 97.2 (C-8). 
 
In the HMBC spectrum (Plate 4G), the singlet resonating at δH 6.63 (H-3) showed a 
correlation to the carbonyl resonance at δC 180.3 (C-4) and the resonance at δC 164.6, which 
could then be assigned to C-2. Both H-2' and H-3' correlated with the resonance at δC 162.9, 
which was assigned to C-4'. The methoxy protons (δH 3.97) showed a long-range 
correlation to the resonance at δC 166.1. Since H-2' and the methoxy protons are correlated 
to two different C-O sp2 carbons, the B-ring must contain a hydroxy substituent and the 
methoxy substituent must be present on the A-ring. Both A-ring aromatic protons (H-6 and 
H-8) showed a correlation with the resonance at δC 166.1, which indicated that the methoxy 
substituent is present at C-7. If the methoxy substituent was at C-5, this correlation would 
have indicated a long-rang coupling from H-8 to C-5, which is less likely. The proposed 
flavone moiety of this compound is given in Fig. 3.13. 
 
 








Figure 3.13. Flavonoid moiety of 3.48. 
 
The remaining parts of both the 1H and the 13C spectra were in agreement with the presence 
of carbohydrate protons and carbons.  The 1H and the 13C spectra indicated the presence of 
four anomeric hydrogens and four anomeric carbons. In the HSQC spectrum, correlations 
were observed between signals at δH 5.10 (d, J 3.8 Hz) and δC  94.0, δH 4.87 (d, J 7.7 Hz) 
and δC 104.7, δH 4.47 (d, J 7.8 Hz) and δC 98.2, and δH 4.33 (d, J 7.4 Hz) and δC 105.7. The 
deprotiated molecular ion [M-H]- in the high-resolution mass spectrum (negative ionisation 
mode) suggested the presence of two carbohydrate moieties only. A careful inspection of 
the NMR spectra indicated that the major compound 3.48 was contaminated with a mixture 
of α- and β-D-glucopyranose, which will be discussed in the next paragraph. The 
carbohydrate moieties with anomeric protons resonating at δH 5.10 and δH 4.47, were 
assigned to this impurity. 
 
Considering the evidence discussed in the previous paragraph, we proposed that compound 
3.48 was a flavone containing a diglycoside substituent on C-5. In the 13C NMR spectrum 
(Plate 4B), eleven carbohydrate carbons were observed for 3.48, in agreement with the 
presence of a hexose and a pentose moiety. These resonances included two anomeric CH 
carbons resonating at δC 104.7 and 105.7, two methylene carbons resonating at δC 70.5 and 
66.9 along with seven CH resonances in the region δC 71 – 78. 
 
The coupling constants of the two anomeric protons resonating at δH 4.87 (d, J 7.7 Hz) and 
δH 4.33 (d, J 7.4 Hz) were characteristic of coupling between diaxial vicinal protons. This 
indicated that both these sugars were β-glycosides and also that the hydrogens on C-2 of 
both sugars were in the axial positions. The linkages of the glycosyl moieties were 
determined by observing the long-range 1H,13C correlations in the HMBC spectrum. The 
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resonance at δC 159.6, which was assigned to C-5. In the HMBC spectrum (Plate 4G), the 
second anomeric proton resonating at δH 4.33 correlated with a methylene carbon resonance 
at δC 70.5, which indicated that the second carbohydrate moiety was linked to C-6'' of the 
first carbohydrate moiety.  
  
By comparison with literature data, the NMR resonances of the first carbohydrate moiety 
agreed with a glucose moiety.184 For the second carbohydrate moiety, the coupling 
constants for H-2''' (δH 3.23, dd, J 9.0 and 7.5 Hz) showed that the protons on C-1,2, and 3 
of this moiety were all in axial positions. The resonances for the methylene group 
associated with the second carbohydrate moiety were observed at δH 3.86 (obscured 
multiplet) and 3.19 (dd, J 11.2 and 10.3 Hz) and δC 66.9. The large chemical shift difference 
between the two methylene protons provided evidence that the methylene group was 
located in a rigid ring and that the pentose moiety was in the pyranose form rather than the 
furanose form. Furthermore, the proton resonating at δH 3.19 (dd, J 11.2 and 10.3 Hz) had 
large geminal and vicinal coupling constants, which was only possible with an axial proton 
on C-4. Based on this evidence, the second carbohydrate moiety was identified as a β-
xyloside. 
 
The structure of 3.48 is indicted below. This compound was previously isolated from other 
plants such as Aquilaria sinensis and was given the name genkwanin 5-O-β-
primeveroside.184 Although using a different solvent (DMSO-d6), NMR data reported for 
3.48 in the literature were in good agreement with our results.185 In Table 3.3, the 
experimental NMR data of 3.48 are compared with those of a derivative of genkwanin 5-
O-β-primeveroside (B-ring is a 3,4,5-trimethoxyphenyl),185 because these data were also 
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Table 3.3  1H NMR (500 MHz) and 13C NMR (125 MHz) spectroscopic data for 
genkwanin 5-O-β-primeveroside (3.48) in CD3OD. 
3.48 3.48 derivative* 
C position Experiment Zahir et al.185 
 δH δC δC δH 
2  164.6 163.1  
3 6.63 (1H, s) 106.8 108.5 6.95 
4  180.3 179.8  
4a  110.4 110.3  
5  159.6 159.4  
6 6.97 (1H, d, J 2.4 Hz) 104.4 104.5 7.03 
7  166.1 166.0  
8 6.95 (1H, d, J 2.4 Hz) 97.2 97.3 7.01 
8a  160.7 61.4  
1'  122.9   
2',6' 7.88 (2H, J 8.8 Hz) 129 .4   
3',5' 6.94 (2H, J 8.8 Hz) 117.1   
4'  162.9   
7-OCH3 3.96 (s) 56.8   
1'' 4.87 (1H, d, J 7.8 Hz) 104.7 104.7 4.80 
2''  75.0 74.7  
3''  77.3 77.2  
4''  71.5 71.5  
5''  77.5 77.4  
6''  70.5 70.4  
1''' 4.33 (1H, d, J 7.5 Hz) 105.7 105.6 4.32 
2''' 3.23 (1H, dd, J 9.0, 7.5 Hz) 74.1 74.2 3.22 
3'''  77.8 77.7  
4'''  71.1 71.1  
5''' 3.19 (dd, J 11.2, 10.3 Hz) 3.86 66.9 66.8 3.18;3.84 
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3.3.6 α- and β-D-Glucopyranose (3.49 and 3.50) 
This material contained compound(s) that were highly polar. In the 13C NMR spectrum of 
3.49 and 3.50 (Plate 5B), 12 signals were observed. The DEPT-135 spectrum indicated that 
10 of these resonances could be assigned to methine carbons and two of the resonances (δC 
62.9 and 62.8) to methylene carbons. The chemical shifts of the two methylene carbons 
were consistent with two OCH2 groups. Two of the methine carbon atoms resonated at 
lower field than the rest of the carbons (δC 98.2 and 94.0), indicating that these two carbons 
were attached to two oxygen atoms each. The other methine carbons resonated at δC 78.1, 
78.0, 76.3, 74.9, 73.8, 73.0, 71.9, and 71.8. All the chemical shifts were consistent with 
aliphatic carbons attached to one oxygen substituent. These data suggested the presence of 
a carbohydrate. Three pairs of resonances had almost the same chemical shifts: δC 78.1 and 
78.0, 71.9 and 71.8, and 62.9 and 62.8. 
 
The 1H NMR spectrum (Plate 5A) supported the assignment of the compound(s) as a 
carbohydrate. Two doublets are observed at δH 5.11 (J 4.0 Hz) and δH 4.48 (J 8.0 Hz), 
consistent with two anomeric protons (H-1), the first resonance characteristic of an 
equatorial proton, indicating an α-sugar, and the second of an axial proton, indicating a β-
sugar. These two protons showed 1JCH coupling with the 
13C resonances at δC 94.0 and 98.2, 
respectively, in the HSQC spectrum. In the COSY spectrum a correlation can be observed 
between the proton resonating at δH 5.11 and a doublet of doublets at δH 3.36 (J 10.0, 4.0) 
and also between the proton resonating at δH 4.48 and a doublet of doublets resonating at 
δH 3.13 (J 9.0 and 7.7 Hz), indicating that the protons on both C-2 and C-3 were axial. In 
the HSQC spectrum, it was observed that the proton resonating at δH 3.36 was attached to 
the carbon resonating at δC 73.9, whereas the proton resonating at δH 3.13 was attached to 
the carbon resonating at δC 76.3. The other 
1H signals were not well resolved. The 
resonances of the protons attached to the carbons resonating at δC 78.1, 78.0, 71.9, and 71.8 
were overlapping with the solvent signals at δH 3.27-3.34, whereas the resonances of the 
protons attached to δC 74.9 and 73.0 overlapped with the resonance of the four methylene 
proton resonances at δH 3.60 - 3.87.  
 
From the data, it was clear that the material consisted of two glucose moieties. These two 
moieties could be attached to form a diglucoside or, alternatively, the material consisted of 
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an equimolar mixture of α- and β-glucose. If it was a diglucoside, long-range 1H,13C 
between H-1 of one unit and the ether carbon of the other carbohydrate unit should have 
been observed. In the HMBC spectrum, the axial anomeric proton (δH 4.48, J 8.0 Hz) did 
not correlate to any carbons, whereas the equatorial anomeric proton (at δH 5.11, J 4 Hz) 
only showed a correlation to the carbon resonating at δC 73.9, which was assigned to C-2 
on the same unit. Therefore, it was clear that this material consisted of an equimolar mixture 
of α- and β-glucopyranose. These two compounds are in equilibrium with each other via 
the intermediate aldehyde, as illustrated in Scheme 3.1 and can normally not be obtained 



























Scheme 3.1.  The equilibrium reaction between α-glucopyranose and β-glucopyranose. 
 
In conclusion, an antidiabetic assay was conducted for the crude and subfractions of the 
leaves extract of B. discolor, confirmed the antidiabetic properties of the plant. Seven 
compounds were isolated from B. discolor, three of them were obtained as a single pure 
compound which are β-sitosteryl linolenate (3.46), α-tocopherol (3.47), and genkwanin 5-
O-β-primeveroside (3.48), while the others were isolated as two mixtures of two 
compounds, i.e. a inseparable mixture of lupeyl acetate (3.44) and its Δ12 isomer (3.45) as 
well as a mixture of α-glucopyranose (3.49) and β-glucopyranose (3.50). Lupeol acetate 
(3.44), its Δ12 isomer (3.45), and β-sitosterol (2.57) have been identified in the literature as 
antidiabetic compounds. Although it was envisaged that sesquiterpenes would be isolated 
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3.4 EXPERIMENTAL 
3.4.1 General experimental procedures 
Analytical grade commercial solvents were used for extraction and chromatography. Ethyl 
acetate, dichloromethane (DCM), and methanol (MeOH) were used directly from the 
suppliers. Hexanes (a mixture of C6 hydrocarbon isomers) was distilled before use. 
Aluminium-backed thin-layer chromatography (TLC) plates (Kieselgel 60 F 254, 0.25 mm) 
were used to detect the different components in a mixture using non-destructive detection 
followed by dipping the plate in a reactive stain reagent and heating it with a heat gun. Non-
destructive detection involves the examination of TLC plates containing a fluorescent 
indicator under a UV lamp at two different wavelengths, short wavelength (254 nm) and 
long wavelength (365 nm). An anisaldehyde/sulfuric acid stain reagent was used to detect 
compounds on TLC plates. This stain reagent was prepared by placing 845 mL of MeOH 
in a 1 L volumetric flask in an ice bath. While continuously shaking and maintaining a low 
temperature, the following reagents were added sequentially: acetic acid (100 mL), sulfuric 
acid (40 mL, dropwise), and anisaldehyde (5 mL, dropwise). This homogenous mixture 
was stored in a fridge. 
Column chromatography was performed on glass columns packed with silica gel 60F254 
(40-63 µm, Merck). The crude samples were applied to the column as dry material 
(adsorbed on silica gel) in case of the large amounts of crude plant extract or as a solution 
(dissolved in the solvent). Solvent systems with different polarities were used to elute the 
material, resulting in separation of compounds. Fig. 3.14 shows a summary of the general 
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Figure 3.14. A summary of column chromatography used for the isolation procedure. 
Centrifugal chromatography, a modified chromatographic technique that combines the 
advantages of TLC and CC, was used to separate smaller amounts of compound mixtures. 
Centrifugal chromatography was performed on a Harrison Research Chromatotron®, model 
7924. The circular plates used were coated with preparative silica gel (1, 2 or 4 mm 
thickness, Merck 7749 with binding agent) and dried in an oven at 50 ᵒC before use. These 
plates were reused after a separation by washing it with MeOH and drying of the plates. 
The sample was dissolved in a small volume of eluting solvent and applied to the spinning 
adsorbent plate using the solvent system for development. Zones were detected by exposure 
of the plate to 254-265 nm UV light and fractions were collected in small vials.  
For chromatography on Diol columns, Applied Separations SPE Diol columns (2 g/ 6 mL) 
were used. These columns were used to fractionate small fractions (100 mg) into 5 
subfractions of different polarities. Diol is a stationary phase in which the silica is 
derivatised with 1,2-dihydroxypropane. This stationary phase is less polar than silica which 
allows it to be used for a wide range of compounds. It is also compatible with a wide range 
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of solvents from hexane through to water. The Diol [-OH] functional group is controlled 
and as such, provides more reproducible separation when compared to separation on 
silanols [-OH] from a bare silica surface.  
NMR spectra were obtained on Bruker Avance III 500 (operating at 500 MHz for 1H and 
125 MHz for 13C) or Bruker Avance III 400 (operating at 400 MHz for 1H and 100 MHz 
for 13C) spectrometers. The NMR experiments used for structural elucidation were 1H, 13C, 
COSY, NOESY, HSQC, HMBC, and DEPT-135. All spectra were recorded in deuterated 
chloroform and methanol at 30 ᵒC using a 5 mm BBOZ probe or 5 mm TBIZ probe. 
Chemical shifts (δ) are given in ppm (part per million) relative to tetramethylsilane (δ = 0) 
and are referenced to residual protonated solvent peaks, for CDCl3:
 1H 7.26, 13C, 77.0 and 
CD3OD: 
1H 3.31, 13C 49.1. Peak multiplicities were abbreviated as follows; s = singlet, d 
= doublet, dd = doublet of doublet, t = triplet, dt = doublet of triplet, and m = multiplet. 
Coupling constant (J) are given in Hz. 
High-resolution mass spectra were collected on a Micromass LCT (Waters) spectrometer 
with electrospray ionization in either the positive or negative mode and with time-of-flight 
detection. 
3.4.2 Collection of plant material 
B. discolor plant material was collected on 8 April 2014 in the University of KwaZulu-
Natal botanical garden and separated into leaves and branches. The leaves and branches 
were carefully examined for any damage. Healthy plant material was dried in a fume hood 
for two weeks. Once it was completely dry, the plant material was ground to a fine powder 
using a hammer mill and stored. B. discolor was identified by Ms Alison Young, curator of 
the botanical garden, University of KwaZulu-Natal, South Africa. A voucher specimen 
(Van Heerden 25) was deposited in the Bews Herbarium, Pietermaritzburg, UKZN. 
3.4.3  Extraction of plant material 
The ground leaves (350 g) were extracted at room temperature for 24 h with a mixture of 
DCM-MeOH (1:1) (750 mL). The plant extract was filtered using Whatman no. 1 filter 
paper and the filtrate was taken to dryness on a rotovap with the water bath set at a 
temperature of 45 ᵒC. The concentrated extract was dried under high vacuum and 19.405 g 
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dry extract was obtained for the leaves. The residual plant material after filtration was then 
extracted with MeOH (750 mL) to yield 9.947 g of MeOH extract of the leaves. The dried 
extracts were stored in the fridge and used as a stock for appropriate applications.  
3.4.4 Fractionation by SPE Diol column 
To obtain fractions with different polarities, 100 mg of crude extract was dissolved in 
DCM-MeOH (1:1) (1 mL per 100 mg of extract per column) and the solution was applied 
to a Diol SPE column. To make sure there is no residual solvent present, the column was 
left to stand overnight and after that, a slight vacuum was applied for 15 min. A sequential 
vacuum elution of the column was performed with the 6 mL of each of the following solvent 
systems: hexanes-DCM (9:1), DCM-EtOAc (20:1), EtOAc, EtOAc-MeOH (5:1), and 
MeOH. Each fraction was transferred to a pre-weighed flask and the solvent was evaporated 
under vacuum. The dry fractions were weighed, transferred to a 2 mL capped vial and 
stored at 0 °C until further analysis. Table 3.4 shows the fractions obtained from the DCM-
MeOH leave extract, their weight and colour description. These fractions were analysed by 
LC-MS and were used for the antidiabetic assay. 
Table 3.4.  Fractions obtained from the crude DCM-MeOH extract of B. discolor 
after separation on a SPE Diol column. 
Fractions  Mass of extract (mg)  Description 
SA-1-5A 19.9 Dark green 
SA-1-5B 9 Dark green 
SA-1-5C 5.2 Light green 
SA-1-5D 10.8 Yellow 
SA-1-5E 46.9 Yellow 
 
Total mass recovered = 91.8 mg 
 
 
3.4.5 Isolation of pure compounds 
The DCM-MeOH (1:1) extract of the leaves of B. discolor (3 g) was subjected to column 
chromatography over TLC grade silica gel. Five fractions (A, B, C, D, and E) were obtained 
after elution with solvents in order of increasing polarity, Hex-DCM (9:1), DCM-EtOAc 
(20:1), EtOAc (100%), EtOAc-MeOH (5:1), and MeOH (100%). All fractions were 
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collected and combined after TLC analysis and weighed to yield; A (164 mg), B (294 mg), 
C (656 mg), D (442 mg), and E (1150 mg). Fraction A was fractionated on the 
Chromatotron (2 mm plate) eluting with hexane-ethyl acetate (98:2) to yield a mixture of 
lupeol acetate (3.44) and its Δ12 isomer, neolupenyl acetate (3.45) as a mixture of 
compounds with the same Rf value (9 mg). The compounds were detected on TLC plates 
by spraying with anisaldehyde reagent and heating it. Fraction B was subjected to column 
chromatography (20 g of silica gel) with Hex-DCM (4:2) as the starting eluent and 
increasing the polarity to 1:1 ratio of the two solvents. Two compounds were obtained and 
they were identified as β-sitosterol (3.46) and α-tocopherol (3.47). Fractions C and D were 
extremely complex mixtures of compounds and were not investigated further. Fraction E 
resulted from MeOH (100%) as eluant. Column chromatography of 150 mg of this fraction 
using DCM-MeOH (9:1), (4:1), (2:1), and (1:1) as eluent resulted in the isolation of two 
fractions. One fraction contained a single compound, genkwanin-5-O-β-D-glucopyranoside 
(3.48), whereas the other fraction consisted of a mixture of two compounds, the α- and β-
isomers of glucose (3.49) and (3.50), respectively. 
The isolation of the compounds from the crude extract are summarised in Fig 3.15 
 
Figure 3.15. A summary of the isolation procedure of the compounds. 
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The physical data for the compounds were as follows: 
Physical data for lupeol acetate (3.44) and its Δ12 isomer (3.45) 
Physical description: Needles 
Melting Point: 211-218°C 
Yield: 9 mg 
Molecular formula: C32H52O2 
NMR data:  
1H NMR:  Plate 1A 
13C NMR: Plate 1B 
DEPT: Plate 1C 
COSY: Plate 1D 
HSQC: Plate 1E 
HMBC: Plate 1G 
NOESY: Plate 1H 
 
Physical data β-sitosteryl linolenate (3.46) 
Physical description: White 
Molecular formula: C47H78O2 
Yield: 2 mg 
1H NMR: Plate 2A 
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13C NMR: Plate 2B 
D COSY: Plate 2D 
DEPT: Plate 2C 
HSQC: Plate 2E 
HMBC: Plate 2G 
NOESY: Plate 2H 
 
Physical data α-tocopherol (3.47) 
Physical description: Oil 
Yield: 3 mg 
Molecular formula: C29H50O2 
ESI-(-)-TOF MS: Observed 429.3737 [M-H]-; calc. for C29H49O2  429.3733 
1H NMR:  Plate 3A 
13C NMR: Plate 3B 
COSY: Plate 3D 
HSQC: Plate 3E 
HMBC: Plate 3G 
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Physical data of genkwanin 5-O-β-primeveroside (3.48) 
Physical description: Pale brown 
Yield: 6 mg 
Melting Point: 200 ˚C  
Molecular formula: C27H30O14 
ESI-(-)-TOF MS: Observed: 557.1554 [M-H]-; calc. for C27H29O14 577.1557 
1H NMR:  Plate 4A 
13C NMR: Plate 4B 
DEPT: Plate 4C 
COSY: Plate 4D 
HSQC: Plate 4E 
HMBC: Plate 4G 
NOESY: Plate 4H 
 
α- and β-D-Glucopyranose (3.49 and 3.50) 
Physical description: white 
Molecular formula: C6H12O6 
Yield: 10 mg 
Melting Point: 146 ˚C  
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1H NMR: Plate 5A 
13C NMR: Plate 5B 
DEPT: Plate 5C 
COSY: Plate 5D 
HSQC: Plate 5E 
HMBC: Plate 5G 
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3.4.5 Evaluation of antidiabetic effects of the crude extract and DIOL column 
fractions 
The effect of extracts and fractions on the glucose utilization in muscle cell line (C2C12) 
was used as an indication of antidiabetic effect of an extract or fractions. These experiments 
were performed by Ntethelelo Sibiya under the supervision of the late Prof C T 
Musambayane in the Physiology Research Group in the School of Laboratory Medicine 
and Medical Science, Westville Campus, University of KwaZulu-Natal. The effects of the 
crude extract of the leaves B. discolor and the fractions obtained after separation on a diol 
column fractions (2A (crude), A, B, C, D, and E) were evaluated by the procedure described 
below and the results are graphically presented in Fig. 3.15  
The muscle (C2C12) cell lines used for the study was donated by the Medical Research 
Council, Cape Town, South Africa. The cells were cultured in 25 mL flasks in DMEM 
(Dulbecco's modified Eagle's medium). Cells were used within 10 passage numbers to limit 
batch-to-batch variation. Culture media were supplemented with 10% foetal calf serum 
(FCS), 1% L-glutamate, and 1% penicillin/ streptomycin/ fungizone. 
Cell culture was conducted using a well-established cell culture protocol. Briefly, muscle 
cells were cultured in 10 mL DMEM at 37 ºC, 5% CO2, and 89% relative humidity. The 
cells could grow and become confluent; thereafter the confluent cells were trypsinised with 
trypsin (1 mL) after washing three times with PBS. The trypsinised cells were sub-cultured 
into new flasks and some were stored in 10% DMSO at -80 ºC for subsequent studies. 
For the experiment, the muscle (C2C12) cells were seeded at a density of 1.5×105 cells/mL 
in a 24-well cell culture plate. The cells were allowed to grow and reach an 80% confluence 
monolayer. The cells were divided as follows: group 1 was treated with media containing 
glucose only, which served as the control, group 2 was treated with a standard drug (insulin 
at 0.04 mg/mL), and group 3 was treated with plant extract at a single dose of 50 µg/mL. 
This experimental protocol was followed for the crude plant extract and fractions obtained 
from the diol column. The glucose utilization experiment was performed as previously 
described by Van de Venter et al.52 with slight modifications. The DMEM contained 28 
mmol/L glucose. After seeded cells reached 80% confluence, the old media was replaced 
with fresh media. Plant extracts (100 µL) and plant extracts + insulin (100 µL) was added 
 
 
73 | P a g e  
 
into the media (1 mL) for treatment in each well. The culture plate was then incubated 
under the above-mentioned conditions. Glucose concentrations were measured at 0, 12, 24, 
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CHAPTER 4: CONCLUSION 
Diabetes mellitus remains a major health problem and a leading cause of death worldwide. 
The number of people living with diabetes is increasing exponentially day after day. Many 
of the current antidiabetic drugs are based on synthetic compounds which are most likely 
to have side effects. Although a limited number of effective antidiabetic drugs from plant 
sources are currently in use, there is still a need for developing effective, safe, and cheap 
antidiabetic drugs. The aim of this thesis was to investigate Brachylaena discolor DC, a 
plant used traditionally for the treatment of diabetes with the specific objectives to confirm 
the antidiabetic activity of an extract of the leaves of B. discolor, isolate the compounds in 
the extract and determine the structures of the isolated compounds. 
The in vitro assaying of the DCM-MeOH extracts of the leaves of B. discolor, showed that 
it had high antidiabetic activity against the C2C12 muscle cells line. The crude extract 
yielded five fractions (A, B, C, D, and E) which led to the isolation of two compounds 
characterised as lupeol acetate and its Δ12 isomer from fraction A. Fraction B also yielded 
two compounds identified as β-sitosterol and α-tocopherol. Fractions C and D showed a 
mixture of compounds which were not further investigated in this study. Finally, fraction 
E afford genkwanin 5-O-β-D-glucopyranoside and a mixture of two compounds, the α- and 
β-anomers of glucose. The antidiabetic activity observed in the DCM-MeOH extract can 
most likely be explained by the presence of these compounds. The available literature 
showed that lupeol acetate, β-sitosterol, and α-tocopherol have antidiabetic properties. The 
isolation of the two lupeol isomers is of particular interest since lupeol is considered as a 
possible drug for diabetes based on its inhibition of the enzyme protein tyrosine 
phosphatase (PTP1B).175 
The results of this study confirm the traditional use of B. discolor to treat diabetes.  While 
these results provide important findings, without doubt each research has some limitations 
which call for future studies. Therefore, the focus of future research could be on the 
investigation of other plant parts such as the branches and roots. The assays on both the 
extracts and pure compounds could be extended to the evaluation of the isolated compounds 
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 Plate 5H: NOESY spectrum of α- and β-D-glucopyranose (3.49) and (3.50) in 
CD3OD. 
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